Biohit Oyj - Total number of voting rights and capital

CONVERSION OF BIOHIT OYJ SERIES A SHARES INTO SERIES B SHARES, AND NOTIFICATION

BIOHIT OYJ STOCK EXCHANGE RELEASE 29 AUGUST 2008 AT 09:30 AM                    

CONVERSION OF BIOHIT OYJ SERIES A SHARES INTO SERIES B SHARES, AND NOTIFICATION 
OF A CHANGE IN SHARE OWNERSHIP IN ACCORDANCE WITH THE SECURITIES MARKETS ACT,   
CHAPTER 2, SECTION 10                                                           

On 28 August 2008, at Professor Pentti Sipponen's request and in accordance with
the Articles of Association, Biohit Oyj's Board of Directors decided to convert 
900,000 Series A shares owned by Sipponen into the equivalent number of Series B
shares. The new Series B shares should be available for public trading on 5     
September 2008, that is, on the day after they are registered in the Trade      
Register.                                                                       

After the share conversion, the number of shares in each class and the votes    
conferred will be as follows:                                                   

--------------------------------------------------------------------------------
|                          |       Number of shares |          Votes conferred |
--------------------------------------------------------------------------------
| Series A shares          |              2,975,500 |               59,510,000 |
--------------------------------------------------------------------------------
| Series B shares          |              9,962,127 |                9,962,127 |
--------------------------------------------------------------------------------
| Total	                  |             12,937,627 |               69,472,127 |
--------------------------------------------------------------------------------

After the Board's decision, on 28 August 2008 Biohit Oyj received notification  
that the combined share of voting rights conferred by shares owned by Professor 
Pentti Sipponen and Patolab Oy - a company in his control - had fallen to under 
one twentieth as a result of the conversion. On 28 August 2008, Biohit Oyj also 
received notification that the combined share of voting rights conferred by     
shares owned by Professor Osmo Suovaniemi, Biocosmos Oy and Interlab Oy - two   
companies in his control - had risen to over two thirds as a result of the      
conversion.                                                                     

In accordance with the Securities Markets Act, Chapter 2, Section 10, Biohit Oyj
is issuing notification that the following changes have occurred in the         
percentage of shares and votes held by Pentti Sipponen, Osma Suovaniemi and     
companies in their control:                                                     

--------------------------------------------------------------------------------
|                           |             No. |     % of shares |   % of votes |
--------------------------------------------------------------------------------
| Osmo Suovaniemi           |                 |                 |              |
--------------------------------------------------------------------------------
| Series A shares           |       2,265,340 |           17.51 |        65.22 |
--------------------------------------------------------------------------------
| Series B shares           |         965,207 |            7.46 |         1.39 |
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
| Biocosmos Oy              |                 |                 |              |
| (Business ID 0551234-7)   |                 |                 |              |
--------------------------------------------------------------------------------
| Series B shares           |         693,735 |            5.36 |         1.00 |
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
| Interlab Oy               |                 |                 |              |
| (Business ID 0201370-2)   |                 |                 |              |
--------------------------------------------------------------------------------
| Series B shares           |         572,762 |            4.43 |         0.82 |
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
| Total                     |       4,497,044 |           34.76 |        68.43 |
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
| Pentti Sipponen           |                 |                 |              |
--------------------------------------------------------------------------------
| Series B shares           |         914,300 |            7.07 |         1.32 |
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
| Patolab Oy                |                 |                 |              |
| (Business ID 0427816-5)   |                 |                 |              |
--------------------------------------------------------------------------------
| Series B shares           |          12,300 |            0.10 |         0.02 |
--------------------------------------------------------------------------------
| Total                     |         926,600 |            7.16 |         1.33 |
--------------------------------------------------------------------------------


Biohit Oyj's share capital consists of 12 937 627 shares. Series A shares confer
twenty (20) votes and Series B shares confer one (1) vote. In payment of        
dividends, however, a dividend of two (2) per cent higher than the nominal value
is paid for Series B shares than is paid for Series A shares.                   


Biohit Oyj                                                                      
Osmo Suovaniemi                                                                 
President and CEO                                                               


Further information:                                                            

Osmo Suovaniemi, M.D., Ph.D., Professor                                         
President & CEO                                                                 
Tel: +358-9-773 861                                                             
GSM: +358-40-745 5605                                                           
Email: osmo.suovaniemi@biohit.com                                               

Distribution:                                                                   

Helsinki Exchanges                                                              
Central storage facility (www.oam.fi)                                           
Press                                                                           
www.biohit.com                                                                  


About Biohit Oyj                                                                

Biohit Oyj develops, manufactures and markets liquid handling products and      
diagnostic test systems for use in research, health care and industrial         
laboratories.                                                                   

Liquid handling products include electronic and mechanical pipettes and         
dispensers, and disposable tips, as well as pipette maintenance and calibration 
services. Diagnostics business comprises products and analysis systems for      
diagnosing, screening and prevention of gastrointestinal diseases, e.g. the     
blood-sample based GastroPanel and GastroView, for diagnosing diseases of the   
stomach and associated risks, as well as biopsy specimen quick tests for the    
diagnosis of lactose intolerance and H. pylori infection.                       

Biohit Oyj is headquartered in Finland. Biohit has subsidiaries in France,      
Germany, the UK, Russia, China, Japan and the USA. Additionally, Biohit's       
products are sold by approximately 450 distributors in 70 countries. Biohit's   
share (BIOBV) is quoted on the Helsinki Exchanges (OMX Helsinki).               

Read more at www.biohit.com